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BACKGROUND: In this study, we appraised a wide assortment of biomarkers previously shown to have diagnostic or prognostic value
for non-small cell lung cancer (NSCLC) with the intent of establishing a multi-analyte serum test capable of identifying patients with
lung cancer.
METHODS: Circulating levels of 47 biomarkers were evaluated against patient cohorts consisting of 90 NSCLC and 43 non-cancer
controls using commercial immunoassays. Multivariate statistical methods were used on all biomarkers achieving statistical relevance
to define an optimised panel of diagnostic biomarkers for NSCLC. The resulting biomarkers were fashioned into a classification
algorithm and validated against serum from a second patient cohort.
RESULTS: A total of 14 analytes achieved statistical relevance upon evaluation. Multivariate statistical methods then identified a panel of
six biomarkers (tumour necrosis factor-a, CYFRA 21-1, interleukin-1ra, matrix metalloproteinase-2, monocyte chemotactic protein-1
and sE-selectin) as being the most efficacious for diagnosing early stage NSCLC. When tested against a second patient cohort, the
panel successfully classified 75 of 88 patients.
CONCLUSIONS: Here, we report the development of a serum algorithm with high specificity for classifying patients with NSCLC against
cohorts of various ‘high-risk’ individuals. A high rate of false positives was observed within the cohort in which patients had non-
neoplastic lung nodules, possibly as a consequence of the inflammatory nature of these conditions.
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Lung cancer remains the second most diagnosed cancer in the
United States and the most common cause of cancer mortality,
with an estimated 161000 deaths in 2008, with 80% being non-
small cell lung cancer (NSCLC) (Mulshine and Sullivan, 2005).
Although the overall prognosis for patients with lung cancer is
poor with a 5-year survival of o15%, patients diagnosed with early
stage disease have a much more favourable prognosis. Patients
with pathological Stages I and II disease have 5-year survivals of
57–67% and 38–55%, respectively (Lu et al, 2004; Singhal et al,
2005). Unfortunately, over half of patients with NSCLC present
only after metastasis to lymph nodes or distant sites because of its
asymptomatic nature at early stages (Lu et al, 2004; Singhal et al,
2005; Wardwell and Massion, 2005). Therefore, the best prospect
for reducing lung cancer mortality remains earlier detection, when
surgery may be curative (Lu et al, 2004; Singhal et al, 2005).
A screening tool capable of early stage detection may allow for
decreased lung cancer mortality.
Although accepted screening programmes for breast, colon,
prostate and cervical cancer have been developed with subsequent
decreases in overall disease mortality, lung cancer-screening
programmes remain in the research realm (McWilliams and
Lam, 2005). There are currently no established methods for
screening individuals at high risk for lung cancer that have been
proven to reduce mortality (MacMahon et al, 2005; Wardwell and
Massion, 2005; Gleeson, 2006). Therefore, screening for NSCLC is
not currently recommended by any major medical association.
Without a nationally defined screening protocol, there is wide
variability in the detection and the initiation of treatment for lung
cancer (Yorio et al, 2009). Since the 1950s, numerous screening
methods have been evaluated for this purpose, including chest
X-ray, sputum cytology, bronchoscopic procedures, low-dose
spiral computed tomography and molecular diagnosis through
nucleic acid or protein biomarkers. These modalities have been
evaluated both alone and in several combinations. Even though no
Received 25 February 2010; revised 19 July 2010; accepted 3 August
2010; published online 21 September 2010
*Correspondence: Dr JA Borgia; E-mail: Jeffrey_Borgia@Rush.edu
7These authors contributed equally to this work
8Current address: Yale University, Section of Thoracic Surgery,
New Haven, CT 06520, USA
British Journal of Cancer (2010) 103, 1221–1228
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sscreening study for lung cancer has proven efficacy in redu-
cing mortality, several of these strategies have improved our
understanding of lung cancer progression and allowed for the
development of potential future screening and treatment
modalities. One of the most promising combinations of these
methodologies consists of low-dose spiral computer tomography
(CT) with a companion serum test (Ashton and Jett, 2005;
Wardwell and Massion, 2005). A spiral CT differs from conven-
tional CT in that it involves continuous motion of the patient
through the machine, which results in a quicker examination and
better visualisation of internal structures, such as blood vessels
and tissues.
Recent advancements in low-dose spiral CT technology have
made improvements towards the detection of NSCLC, but its
ability to reduce mortality from NSCLC has yet to be established
(Ashton and Jett, 2005; Wardwell and Massion, 2005; Gleeson,
2006). With the relatively high cost of spiral CT, the high rate of
false positives leading to unnecessary biopsy or surgery, and the
need for serial measurements to confirm non-neoplastic disease,
addition of an economical serum test to the CT-screening protocol
could improve specificity and cost effectiveness. A serum test
could be used as an initial screen to assess NSCLC risk, and select
for a smaller population that requires further screening with spiral
CT. Alternately, a serum test might also be useful in discriminating
between non-neoplastic disease and malignancy for a questionable
nodule found by CT, thereby eliminating the need for serial CTs
or invasive biopsy. We have already successfully validated
a biomarker panel with significant sensitivity and specificity for
more accurately defining pre-operative nodal status in NSCLC, and
we hope to bring a similar diagnostic tool into the screening realm
(Borgia et al, 2009).
In this study, we have selected an array of 47 candidate
biomarkers implicated in NSCLC and screened a total of 135
patients (n¼90 NSCLC; n¼43 controls) to evaluate whether we
can identify a panel of biomarkers with significant test perfor-
mance characteristics for differentiating between patients with
early stage NSCLC and our control population. We selected
candidate biomarkers based on reports in the literature for having
value in discriminating NSCLC from control populations (Hatzakis
et al, 2002; Neuner et al, 2002; Molina et al, 2003; Kaya et al, 2004;
Onn et al, 2004; Pujol et al, 2004; Boldrini et al, 2005; Huang et al,
2005; Tarro et al, 2005; Vielh et al, 2005; D’Amico et al, 2006;
Kaminska et al, 2006; Xi et al, 2006). Our principal objective was to
develop a multi-analyte blood test capable of screening for NSCLC
either as a stand-alone diagnostic measure or as a companion test
for current CT-based-screening protocols.
MATERIALS AND METHODS
Patient populations
Serum specimens were obtained from 90 NSCLC patients as well
as two different groups of controls (n¼43) to approach the
complexity that ‘high-risk’ populations pose to a diagnostic
measure of this type. All NSCLC patients and controls were
obtained in full compliance with the Institutional Revue Board at
Rush University Medical Center (RUMC), including formal written
consent. Diagnosis confirmation for the NSCLC cohort was
obtained from surgical pathology reports on tissue gathered from
tumour resection with lymph node dissections. Criteria for study
inclusion in the NSCLC cohort were broad (consisted of having a
surgical resection with pathological evaluation) and were not
limited to any demographic or clinical factor. Control specimens
(n¼31) were obtained from the Department of Rheumatology
RUMC and were all involved in a study of osteoarthritis
progression. This cohort was selected on the basis of similar
demographic characteristics (with respects to age and sex) and had
a diagnosed condition with an inflammatory component. A total of
7 out of the 31 patients had a significant smoking history. At the
time of specimen accrual, and in clinical follow-up data, these
patients had no evidence of any pulmonary disorders or
carcinomas of any type. The ‘non-neoplastic disease after surgery’
group consisted of 12 patients with granulomas, pneumonitis or
pneumonia. These patients underwent resection secondary to
concern for cancer or persistent symptoms after conservative
management.
The specimens used for panel validation consisted of the
following cohorts: an NSCLC cohort (n¼33 total) consisting of 25
Stage I, 7 Stage II and 1 Stage III NSCLC patients, all collected at
RUMC. A second control cohort of 15 non-neoplastic lung disease
patients with surgically resected ‘questionable’ lesions (all from
RUMC), and a ‘non-neoplastic disease without surgery’ group
consisting of 40 patients with chronic obstructive pulmonary
disease (COPD) or asthma were also used in the validation studies.
Patients from this COPD/asthma group were seen clinically based
on complaints of cough development or change in respiratory
symptoms; serum was collected immediately preceding broncho-
scopy and CT imaging was then used to evaluate for the presence
of pulmonary nodules. The specimens were generously provided
by Abbott Laboratories (Abbott Park, IL, USA) without any patient
identifiers or clinical follow-up data beyond that associated with
serum acquisition. The overall COPD/asthma cohort from which
these cases were selected possessed a smoking history similar to
the NSCLC cohort (median value of 40 pack years). Phlebotomy
protocols and methods for serum preparation for both of these
groups were consistent with those we previously described (Borgia
et al, 2009).
Collection and storage of serum specimens
Peripheral blood collected at RUMC was obtained from each
patient immediately before treatment initiation using standard
phlebotomy techniques, with all samples handled and processed in
an identical manner, as previously described (Borgia et al, 2009).
No specimens were subjected to more than two thaw cycles for this
study. Control sera were collected in an identical manner and
processed as described above.
Measurement of serum biomarker concentrations
Whenever possible, the Luminex xMAP immunoassay platform
was used to measure the circulating levels of biomarkers reported
in this report, with ELISA-based immunoassays encompassing
only 2 out of the 47 biomarkers tested. These were all performed
according to the manufacturer’s suggested protocols and were
conducted in the following groupings at the Rush Biomarkers and
Proteomics Core Facility: C-reactive protein (CRP) and serum
amyloid A (Millipore, Billerica, MA, USA); interleukin-1b (IL-1b),
IL-1ra, IL-6, IL-8, IL-10, tumour necrosis factor-a (TNF-a) and
transforming growth factor-a (TGF-a) (Millipore); IL-2, IL-13,
interferon-g (IFN-g), IFN-inducible protein 10 and granulocyte
monocyte colony-stimulating factor (GM-CSF) (Bio-Rad Labora-
tories, Hercules, CA, USA); IL-1a, IL-2Ra, M-CSF, stem cell-
derived factor 1a (SDF-1a) and stem cell factor (Bio-Rad
Laboratories); sE-selectin, sP-selectin and soluble intracellular
adhesion molecule 1 (R & D systems, Minneapolis, MN, USA);
matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9 and MMP-13
(R & D Systems); death receptor 5 (DR5), tissue necrosis factor –
receptor I (TNF-RI) and TNF-RII (Invitrogen, Carlsbad, CA,
USA); RANTES, macrophage inflammatory protein-1a (MIP-1a),
MIP-1b, monocyte chemotactic protein-1 (MCP-1) and eotaxin
(Invitrogen); granulocyte colony-stimulating factor, epidermal
growth factor, vascular endothelial growth factor and basic
fibroblast growth factor (Invitrogen). In addition, sEGFR
(erb-b1), Her-2 (erb-b2), CA125, CA15-3, CA19-9, CEA and
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sCYFRA 21.1 were measured at the University of Pittsburgh Cancer
Institute’s Luminex Core Facility (Dr Anna E Lokshin, Director)
on a fee-for-service basis. All biomarker concentrations were
calculated through a five-parametric curve fit as part of the BioPlex
Suspension Array System Software v4.0 (Bio-Rad Laboratories).
Measurements of TIMP-1 and osteopontin concentrations were
conducted using commercially available ELISA assays and in
accordance to the kit directions (R & D Systems). Data were
collected on a BioTek PowerWave XS plate reader using KC Junior
(v1.40.3) software package. A four-parametric curve fit was used
to calculate the concentrations from the raw absorbance readings.
All assays performed for this study were conducted in a blinded
manner and were statistically processed by different personnel to
minimise operator bias.
Validation studies used the identical commercially available
kits for 14 of the analytes evaluated, following manufacturer’s
instructions in the following groupings: CRP (Millipore); IL-1ra,
IL-6, IL-10, and TNF-a (Millipore); IFN-g (Bio-Rad Laboratories);
IL-2Ra (Bio-Rad Laboratories); sE-selectin and sP-selectin (R & D
systems); MMP-2 (R & D Systems); MIP-1a, MCP-1, and eotaxin
(Invitrogen); CA125 and CYFRA 21.1 was again were measured at
the University of Pittsburgh Cancer Institute’s Luminex Core
Facility. The data was collected in the same manner and a five-
parametric curve fit was use to calculate the concentrations from
the raw absorbance readings.
Statistical methods
Individual biomarker evaluation Using SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL, USA), descriptive statistics (median,
range) and graphical displays (histogram, box plot, normal
probability plot) for concentrations of each biomarker were
obtained. When using manufacturer’s suggested dilution factors,
data sets with o66% of the total values within the range of the
assay were discarded (arbitrary threshold), whereas data sets with
only a small portion of the data missing (because of values being
reproducibly immediately below the assay range) had missing
values either extrapolated or the lowest measured value used in its
place. Overall, the data exhibited a departure from normal
statistical distributions and, therefore, the Mann–Whitney rank
sum test was used to assess the differences in biomarker
concentrations between any of the groups. A threshold for
significance was set to Pp0.05. Receiver operating characteristic
(ROC) curves for predicting patient’s lung cancer was also
calculated for each individual biomarker, with the criteria for
relevance set to an area under the curve (AUC) value of X0.65.
Multivariate analysis The multivariate analysis was performed
on an initial panel of biomarkers selected based on univariate
analysis. The inclusion criteria for the individual biomarkers in
the initial panel was a Mann–Whitney rank sum (two-sided test)
P-value o0.05 or an area under the ROC curve (AUC) 40.65; the
goal was to include all candidate markers of potential value. The
multivariate analysis resulted in a final multivariate panel of
biomarkers selected from the initial candidate panel based on
statistical variable selection performed within the Random Forests
package in R (Breiman et al, 1984; Breiman, 2001). This use of
Random Forests has been previously described in detail by our
group (Borgia et al, 2009).
The final multivariate panel of biomarkers resulting from the
Random Forest variable selection process was then used by a
Classification and Regression Tree (CART) algorithm to model a
classification tree that predicts NSCLC diagnosis (yes/no) of each
patient based on his/her biomarker panel. This analysis was
performed using the RPART package of the R statistical software
suite (Team, 2007). The predicted probability of a patient having
NSCLC from the classification tree was then compared with the
pathology-based NSCLC diagnosis to obtain sensitivity and
specificity across a range of cut points for decision rules and the
resulting ROCs curve.
RESULTS
Analysis of individual serum biomarkers according to
diagnostic value
Our initial selection consisted of an array of 47 biomarkers; they
were selected based either on published reports for each biomarker
showing value for at least one of the following functions: NSCLC
diagnosis, staging or prognosis (Hatzakis et al, 2002; Neuner et al,
2002; Molina et al, 2003; Kaya et al, 2004; Onn et al, 2004; Pujol
et al, 2004; Boldrini et al, 2005; Huang et al, 2005; Tarro et al, 2005;
Vielh et al, 2005; D’Amico et al, 2006; Kaminska et al, 2006;
Xi et al, 2006) or involvement in biological processes implicated in
disease progression. The levels of these markers were evaluated in
sera from 90 NSCLC patients treated at RUMC and 43 non-cancer
controls. Table 1 shows the clinical and pathological characteristics
of patients. Several biomarkers, including IL-1a, IL-1b, IL-2, IL-15,
GM-CSF, TGF-a, DR5, MMP-13, had a significant portion of their
measurements fall below the threshold of assay range (using the
Table 1 Characteristics of patient populations
Discovery Validation
I II III I II III
Age
Range 40–83 47–80 46–84 40–80 49–92 46–84
Median 67.5 62 69 61 70 68
Sex
Male 3 9 38 6 21 17
Female 9 22 52 9 19 16
NSCLC stage
a
Ia 16 11
Ib 37 14
IIa 2 2
IIb 11 5
IIIa 19 1
IIIb 5 —
Diagnosis
Adenocarcinoma 57 18
Squamous 30 10
Adenosquamous 1 2
NSCLC – other 2 3
Condition
No lung pathology 31
Granuloma 5 6
COPD 1 34
Asthma 6
Sarcoidosis 1
Pneumonitis 1 1
Pneumonia 2 1
Benign cyst 1
Hamartoma 2
Chronic inflammation 2
Lymphoid infiltrate 1
Thymoma 1
Lipoma 1 1
Discovery group refers to the initial group of patients on which 47 biomarkers were
tested and multi-analyte panel was created, groups are as follows: I¼resected non-
neoplastic disease; II¼rheumatology controls; III¼NSCLC patients. Validation group
refers to second cohort on whom our six-multi-analyte panel was tested, groups are
as follows: I¼resected non-neoplastic disease; II¼COPD/asthma patients;
III¼NSCLC patients.
aPathologic stage.
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from further analysis. These biomarkers exhibited no apparent
trends in the raw data warranting reanalysis.
Serum concentrations of TNF-a, CYFRA 21.1, IL-1ra, IL-6,
IFN-g, IL-2Ra and CA125 were found to be significantly higher in
the NSCLC group (Mann–Whitney rank sum (two-sided) test
P-values p0.001), whereas the concentration of MCP-1, CRP,
MMP-2 and sE-selectin were found to be significantly higher in the
control group (P-values p0.001). Using a significance threshold of
a Mann–Whitney rank sum (two-sided) test P-value o0.05 or
analysis of the ROC curve ‘AUC’ 40.65, a total of 14 biomarkers
were found to be suitable to undergo multivariate analysis. A list of
these biomarkers along with the statistical parameters for each is
included in Table 2. No significant differences were observed upon
examination of biomarker levels associations with age, smoking
history and fasting status (all P-values were 40.1).
Classifications based on a multi-analyte panel for
identifying early detection of NSCLC
A panel of 6 biomarkers was selected from the 14 biomarkers
meeting our inclusion criteria for statistical relevance using the
Random Forests algorithm, as defined in Materials and methods
section. The averaged out-of-bag ‘misclassification errors’ as well
as the AUC from the range of the 1000 trees of the Random Forest
grown for each of their respective sub-panels are shown in Table 3.
We found that the continued ‘focusing’ of the panel from the
14 individual biomarkers to the six-analyte panel improved our
ability to correctly classify patients relative to the pathological
NSCLC status. However, after the fifth iteration, the AUC and
associated sensitivity and specificity values (data not shown)
decreased as the number of biomarkers decreased leading us to
select the six-member panel from this fifth iteration as the most
optimal combination for detecting NSCLC. Individual ‘box and
whisker’ plots are shown for these six biomarkers in Figure 1. Next,
we defined a classification tree based on a sub-panel of six markers
(consisting of TNF-a, CYFRA 21.1, IL-1ra, MMP-2, MCP-1,
sE-selectin) selected from the Random Forest algorithm within
the RPART software package to provide a convenient and useful
algorithm for distinguishing NSCLC from benign controls. The
classification tree resulting from this process is represented in
Figure 2. This tree correctly classified 127 out of the 133 cases
(a correct classification rate of 95%). The ROC curve for this
classification tree is shown in Figure 3. Test performance
characteristics for this panel boast a 97.9% AUC translating to
99% sensitivity and 95% specificity. As reported in our previous
studies using this strategy (Borgia et al, 2009), we observed a
substantial gain in our ability to screen for NSCLC when using the
multi-analyte panel over any individual biomarker.
When we validated the performance characteristics of this
six-analyte panel that were validated against a second patient
cohort, we successfully classified overall 75 of 88 patients.
Table 2 Biomarkers selected for multivariate analysis based on statistical relevance
Resected benign
nodules (n¼12)
‘Normal’
controls (n¼31)
NSCLC:
Stage I
a (n¼55)
NSCLC:
Stages II & III
a,b (n¼37)
Overall performance
characteristics
Biomarker Median
c Range
c Median
c Range
c Median
c Range
c Median
c Range
c AUC P-value
d
CYFRA 21-1 371.9 227–783 277.54 122.3–617.2 630.89 169.5–5351 674.56 293.4–3663 0.873 o0.001
TNF-a 8.92 3.7–27 4.06 1.37–11.94 14.35 1.37–140 13.85 2.9–41.93 0.862 o0.001
MCP-1 0.47 0.28–1.07 0.77 0.2–2.34 0.40 0.18–2.06 0.4 0.12–5.7 0.753 o0.001
IL-1ra 184.2 42–1168 81.59 2.41–606.4 326.93 2.41–2144 326.93 1.12–3258 0.719 o0.001
MMP-2 6792 4440–10013 7757 5029–12836 6195 3293–12693 5516 897–10094 0.705 o0.001
IL-6 37.59 1.17–1495 11.39 1.17–1520 61.46 1.17–5862 54.99 3.44–906.5 0.702 o0.001
EOTAXIN 0.135 0.07–0.23 0.16 0.06–0.26 0.10 0.04–0.39 0.11 0.04–0.56 0.698 o0.001
CA-125 1.13 0.43–11.47 0.57 0.12–4.92 1.38 0.12–143.4 1.8 0.1–24.6 0.698 o0.001
sE-selectin 1643 702–3962 1635 862–4079 1198 417–2603 1283 509–2547 0.690 o0.001
sP-selectin 2779 1265–8764 3168 1722–5158 2726 926–5181 1892 926–11835 0.677 o0.001
MIP-1a 0.13 0.1–0.15 0.14 0.12–0.21 0.13 0.1–0.7 0.12 0.05–0.81 0.669 0.00117
IL-10 21.32 3.04–92.08 3.04 3.04–576.6 16.83 3.04–1361 42.5 3.04–428 0.667 0.00162
CRP 2.659 0.945–4.336 4.89 0.945–23.7 2.69 0.95–10.2 3.05 0.015–9.92 0.662 0.00245
IL-2Ra 54.4 18.7–119.7 29.815 5.33–224.62 57.44 5.33–3359 46.98 7.03–192.8 0.652 0.00462
aPathologic stage.
bLymph node-positive disease.
cValues expressed as pgml
–1.
dMann–Whitney U (two-sided test). Descriptive statistical parameters and individual test
performance characteristics measured from our training cohort for each biomarker within our statistical thresholds. Abbreviations: NSCLC¼non-small cell lung cancer;
AUC¼area under the curve; TNF¼tumour necrosis factor; MCP¼monocyte chemotactic protein; IL¼interleukin; MMP¼matrix metalloproteinases; CA¼cancer antigen;
MIP¼macrophage inflammatory protein; CRP¼C-reactive protein; CYFRA¼CYFRA 21-1, cytokeratin 19 fragment.
Table 3 Variable selection of biomarkers using Random Forests
Biomarkers
Variables MIP-1a SCF CEA TNF-RI TNF-a IFN-c M-CSF G-CSF TNF-RII sICAM-1 MMP-2 CRP IL-2Ra Osteopontin IL-1ra OOB
1 15 X X X X X X X X X X X X X X X 0.336
2 12 X X X X X X X X X X X X 0.308
3 10 X X X X X X X X X X 0.308
4 8 X X X X X X X X 0.317
56 X X XX XX 0.308
65 X X XX X 0.289
74 X X XX 0.345
Abbreviations: OOB¼out-of-bag (misclassification error); TNF¼tumour necrosis factor; IL¼interleukin; MMP¼matrix metalloproteinases; MIP¼macrophage inflammatory
protein; CRP¼C-reactive protein; SCF¼stem cell factor; IFN¼interferon; G-CSF¼granulocyte colony-stimulating factor; M-CSF¼monocyte colony-stimulating factor;
sICAM-1¼soluble intracellular adhesion molecule 1.
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means to confirm the relevance of the associations of the
individual biomarkers with promise for the panel to screen for
NSCLC. When looking solely at the cohort composed of COPD and
asthma patients, only a single patient was misclassified (false
positive) of the 40 tested. In the NSCLC cohort, five patients were
misclassified of the 33 patients, resulting in an 85% classification
rate. Misclassifications were not limited to Stage IA patients,
possibly indicating that errors were not due to test sensitivity. And
finally, only 8 out of the 15 patients with resected, non-neoplastic
disease were correctly classified. This sub-group may require
further development in order to improve the range of patients that
can be accurately classified by this methodology.
DISCUSSION
Chest radiography has been widely used historically as a
preliminary screening tool because of its wide accessibility,
relatively low cost and ease of use. Radiographs, however, have
very low specificity and sensitivity when compared with more
contemporary imaging techniques such as CT (Ashton and Jett,
2005; Wardwell and Massion, 2005). Therefore, radiography has
had very modest success in diagnosing early stage disease.
Screening trials have shown that chest radiographs fail to detect
60–80% of early stage lung cancers that were found in the same
study by CT (MacMahon et al, 2005; McWilliams and Lam, 2005;
Mulshine and Sullivan, 2005; Gleeson, 2006). Recent spiral CT
advancements have made the method more effective in detecting
tumours at a resectable stage than any other modality currently
being used for NSCLC. Despite the promising results obtained
from the recent spiral CT studies with an increase in early stage
disease seen over historical controls, CT screening has not yet been
shown to reduce mortality from NSCLC. In addition, CT-screening
protocols have several limitations. For example, given the
relatively high sensitivity of the technique, coupled with its low
specificity, many benign lesions appear as questionable, non-
calcified nodules (McWilliams and Lam, 2005; Wardwell and
Massion, 2005). These lesions frequently require serial screening to
evaluate for growth or more definite neoplastic traits. The interval
needed to discern which lesions are neoplastic through serial CT
scans may be a critical period in the progression of NSCLC
(MacMahon et al, 2005; McWilliams and Lam, 2005; Wardwell
and Massion, 2005). Therefore, spiral CT is commonly used in
combination with a second diagnostic means, such as PET
imaging, to attain a more immediate diagnosis. However, the cost
of combined imaging modalities may be prohibitive for any
widespread screening programmes for early stage disease. Another
method routinely used to discern these questionable nodules is the
combination of spiral CT with CT-directed fine needle aspirates or
bronchoscopy. However, the anxiety and discomfort associated
with these invasive techniques make them less than ideal for
screening asymptomatic patients. A low cost and minimally invasive
serum test would be a much preferred means to complement spiral
CT or potentially serve as a pre-screening method to minimise the
overall costs of NSCLC detection by better selecting patients to
undergo spiral CT. Although no FDA-approved test of this sort
currently exists, advancements in the fields of genomics and
proteomics bring this screening option closer to reality.
For this study, we used a high-throughput discovery strategy
using an extensive arsenal of biomarkers implicated in the
literature as having diagnostic and/or prognostic value for NSCLC.
The Luminex immunobead platform was important to this
strategy, given the ability to process the serum specimens
efficiently, whereas using low microliter quantities per panel
tested. With the patient cohorts evaluated here, we identified a
serum test consisting of TNF-a, CYFRA 21.1, IL-1ra, MMP-2,
MCP-1 and sE-selectin. The cytokeratin 19 fragment, CYFRA 21.1,
is perhaps the most extensively characterised biomarker with
diagnostic value for NSCLC (Stieber et al, 1993; Bates et al, 1997;
Molina et al, 2003; Tarro et al, 2005). Numerous studies have been
focused on evaluating its potential for early detection of NSCLC as
well as its potential prognostic and predictive value. Each of the
remaining analytes has also been previously implicated individu-
ally as having either diagnostic value or a function in inflamma-
tion, either in NSCLC or other carcinomas. More specifically,
TNF-a, and IL-1ra are both considered to be acute phase reactants,
and as such, they are involved in modulating the immune response
and show increased expression in an inflammatory state. Cancer
cells are immunogenic and, therefore, lead to the increased
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Figure 1 Box plots for the 6 biomarkers identified by the Random Forest algorithm. Box plots for the six selected biomarkers selected by the Random
Forest analysis on the discovery cohort. Abscissa labels: 0¼surgically resected, non-neoplastic nodules, 1¼‘normal’ controls, 2¼Stage IA NSCLC,
3¼Stage IB NSCLC and 4¼Stages II and III (node positive) NSCLC. Notes: disease staging is based on pathologic stage; extreme values are not shown in
the plots. Significance (Mann–Whitney Rank sum test) is shown with bars above boxes with a¼Po 0.001; b¼Po0.01 and c¼Po0.05.
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sexpression of proinflammatory agents as well as associated
secondary biomarkers. There is an association between chronic
inflammation and tumourigenesis, largely because of increases in
cell turnover, which can increase serum biomarkers (Yao and
Rahman, 2009). Similarly, sE-selectin is a cell adhesion molecule,
frequently modulated by inflammation. The MMP-2 is involved in
the degradation of proteins in the extracellular matrix during
tissue remodelling for epithelial reorganisation.
In terms of performance against the sub-populations within our
validation cohorts, our multivariate panel was able to correctly
classify most patients with NSCLC as having NSCLC (15% false-
negative rate), as well as patients within the Abbott cohort (2.5%
false-positive rate) as not having NSCLC. It is difficult to speculate
on the possible reasons for the single case of a false positive we
observed within Abbott cohort; other than the patient had
diagnosed COPD, there was limited clinical data available to us
for this patient. However, it is conceivable that this patient may
have had undiagnosed or ‘pre-cancerous’ lesions that we detected
with our serum test at the time of serum accrual. The sub-
population that was the most difficult to classify correctly was the
patients with resected non-neoplastic lung disease. Of the patients
from this group that were misclassified (47% rate of false
positives), all had an inflammatory condition (i.e. pneumonia,
pulmonary abscess, hepatitis C) that may have (at least in part)
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Figure 2 Classification and Regression Tree for Final Panel. Classification and Regression Tree for predicting whether a patient is positive for NSCLC.
Briefly, the algorithm represents a series of binary ‘if-then’ decision rules that are used to split the data into separate branches of the tree. Each node of the
tree displays the analyte being considered and the threshold concentrations used to partition the patient groups. Additional classifications continue along
each arm of the split in which it is indicated whether the measured value is either less than or equal to or exceeding the indicated threshold cutoff value.
The number of classifications (observations) are listed at each terminal node, with each final arm labelled (0¼NSCLC negative; 1¼NSCLC positive).
Abbreviations: obs.¼observations; TNF-a¼tumour necrosing factor-a; MCP-1¼monocyte chemotactic protein-1; MMP-2¼matrix metalloproteinase-2
and IL-1ra¼interleukin-1 receptor antagonist.
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Figure 3 The ROC curve for the six-analyte serum test. ROC curve
for the optimised six-analyte CART algorithm using the original training
cohort of patients. Area under the curve¼0.979; sensitivity¼99%;
specificity¼95%.
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smimicked the biomarker profile that classifies patients as having
NSCLC. Symptom severity upon presentation may have elevated
these factors in the group that were suspected of having neoplastic
lesions relative to patients with a similar set of pathologies, but
were exclusively treated in the clinic (such as in the COPD/asthma
cohort). With this, future development of the serum test will focus
on biomarkers not directly related to inflammation in order to
improve specificity of this test and the rate of positive classifica-
tions, such as circulating tumour-specific autoantibodies. Given
the differences in the measured values across the various groups, it
seems unlikely that there was a bias towards patients receiving
surgery vs those that were treated on an outpatient basis.
Earlier to the report of the panel presented here, the combination
of CEA, CA125, CA 19-9, CYFRA 21-1 and NSE was the most
efficacious serum test for diagnosing NSCLC, with reported test
performance characteristics of a 93.8% sensitivity and 71.5%
specificity (Chen et al, 2008). Although this panel offers excellent
sensitivity, it has poor specificity, making it incapable of serving as a
means to complement spiral CT-based-screening protocols and
inadequate to serve as a ‘stand-alone’ diagnostic method.
On the basis of the results presented here, we conclude that our
NSCLC detection algorithm bases on six serum biomarkers may be
a promising low cost and minimally invasive screening test for
patients at high risk for NSCLC. Further validation studies are
needed to confirm the relevance of this detection algorithm and,
ultimately, help bring this much needed screening test into common
use. There has also been some consideration of using serum
autoantibodies for the early detection of lung cancer (Chapman
et al, 2008; Tan et al, 2009). To further increase the sensitivity and
specificity of this panel, the addition of autoantibodies to our present
panel is currently in development by our laboratory. We anticipate
that the addition of biomarkers of this type may offer the test
specificity necessary to discern patients with inflammatory nodules
requiring resection from the cases of NSCLC.
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